298 results about "Stromal cell" patented technology

The invention discloses carboxymethyl chitosan-hyaluronic acid-stem cell exosome eye drops as well as a preparation method and application thereof, and relates to the technical field of eye drops and medical biogel. The carboxymethyl chitosan-hyaluronic acid-stem cell exosome eye drops are prepared from tannic acid modified carboxymethyl chitosan and adipose tissue-derived stromal cell exosome freeze-dried powder, the carboxymethyl chitosan-hyaluronic acid-stem cell exosome eye drops provided by the invention can effectively treat xerophthalmia, and are stable in components, safe and reliable. The three components including the tannic acid modified carboxymethyl chitosan, the hyaluronic acid and the adipose tissue-derived stromal cell exosome coexist, so that the functions of all the components can be fully played, a synergistic effect is achieved, and a better treatment effect on xerophthalmia is achieved.

The invention discloses a sebastes schlegeli testis cell line as well as a construction method and application thereof, and belongs to the technical field of marine fish cell culture. Primary culture and subculture are carried out on sebastes schlegeli juvenile fish testis tissues, so that the sebastes schlegeli testis cell line capable of being continuously subcultured in vitro for a long time is established. The sebastes schlegeli testis cell line established by the invention is in a fibroblast shape, has a good growth curve, and has relatively strong multiplication capacity. The lentiviral vector can significantly express the stromal cell marker gene temp2, can transfect the cell line, and can be subsequently applied to research of gonad development related functional genes. At present, the cell line has been subjected to in-vitro continuous passage for more than 60 generations, can be subjected to cryopreservation, and is high in recovery survival rate. Establishment of the cell line provides a stable and excellent experimental material for research of fish gonad development genes.

The invention belongs to the technical field of functional nanoprobes and biological detection, and particularly relates to a kit for simultaneously detecting a specific membrane protein marker and a membrane protein dimer and application of the kit. The detection kit comprises a membrane proteome anchoring chain, a recognition probe, an SERS probe and an auxiliary signal amplification reagent, by combining DNA logic sensing based on aptamer recognition and logic response type assembly based on EpCAM protein expression and DNA signal amplification of Met protein dimerization, networked assembly of a recognition probe and an SERS probe is realized, so that specific accurate recognition of tumor cells and high-sensitivity SERS detection and imaging of membrane protein dimers are realized; the method is suitable for monitoring an HGF / Met signal channel based on Met protein dimerization mediation between stromal cells and cancer cells in a complex tumor microenvironment, and can evaluate the inhibition effect of a targeted drug on receptor dimerization in real time.

The invention provides a screening platform for chemotherapy combined anti-tumor natural products and application of the screening platform. PTC has tumor cells, interstitial cells, fibroblasts and immune cells from primary epithelium, is rich in cell components, and has advantages in the aspect of tumor microenvironment simulation. Meanwhile, PTC can reproduce tumor heterogeneity, the culture success rate and clinical consistency can reach 90% or above, and the detection period is within two weeks. And the detection result can be read through AI intelligent software, so that the accuracy can be further improved. The screening period can be shortened, the cost is reduced, and the accuracy is improved; according to the platform, high-throughput screening can be carried out in a short time, and the treatment effect of a chemotherapy drug combined anti-tumor natural product drug scheme can be predicted.

The invention belongs to a molecular biological technology, discloses a construction method of a uterus stromal specific gene editing mouse, and relates to a CRISPR-Cas9-based stromal specific gene editing mouse. The Cre mouse using Vim as a specific promoter activates Cas9, and the Cas9 mouse not only solves the problem of complex breeding of the traditional Cre mouse, but also can realize tissue specific knockout without homozygosis. Cas9 mice can be used for knocking out various sgRNAs, and more possibilities are provided for development of a gene editing model. The obtained Cas9 mouse is mated with an sgMettl3 report mouse, and the Mettl3 gene is successfully knocked out in the uterine stromal cells in a guided manner. The invention provides a valuable gene editing model for endometrial gene research, and overcomes the challenge of difficult knockout of bispecific site mediated genes.

The invention is directed to methods of improving the therapeutic efficacy of mesenchymal stromal cells (MSCs) for use in treating osteoarthritis (OA), and more specifically to methods of altering levels of certain proteins, phospho-proteins, genes, and / or MSC-secreted cytokines, chemokines, and / or growth factors in order to improve therapeutic efficacy, as well as methods of distinguishing and classifying MSCs as being highly therapeutic or less therapeutic based on levels of certain phospho-proteins and / or MSC-secreted cytokines, chemokines, and / or growth factors and methods of treating a subject having OA with MSCs having improved therapeutic efficacy.

Aspects of the present disclosure provide engineered induced pluripotent stem cell (iPSC)-derived mesenchymal stromal cells (EiMSCs) that exhibit persistent transgene expression. Persistent transgene expression may be achieved through use of an engineered chromatin opening sequence (ECOS). The engineered EiMSCs of the present disclosure can comprise a therapeutic polypeptide comprising one or more cytokines for the treatment of a metabolic disease, a proliferative disease, an autoimmune disease, a neurological disease, or any combination thereof.

The invention relates to the technical field of preparation and application of a co-polymer biological material, and discloses a matrix-cell co-polymer biological material, which comprises a matrix-cell co-polymer, and the matrix-cell co-polymer comprises human decellularized alveolar bone matrix microparticles and human dental sac stem cells. According to the matrix-cell copolymer biological material as well as the preparation method and the application thereof, hDABMPs capable of providing a tissue-specific microenvironment and hDFSCs with development potential are utilized to prepare a developmental bionic matrix-cell copolymer biological material, and the developmental bionic matrix-cell copolymer biological regeneration material has good mechanical strength, good mechanical properties, good biocompatibility, good biocompatibility and good biocompatibility. The stem cell polymer carrying the tissue-specific microenvironment and the developmental potential provides key biological signals of a regeneration scaffold and the specific tissue microenvironment for tissue regeneration so as to support and enhance the regeneration capacity of the implanted stem cell polymer. The strategy highlights the synergistic effect of development guidance and microenvironment induction.

Disclosed is a method for producing T cells, the method comprising: (1) culturing three-dimensional cell aggregate(s) comprising cells that can differentiate into T cells, and stromal cells that express Notch ligand(s) derived from pluripotent stem cells. Also disclosed are T cells obtained by the method, and a medicine comprising the T cells.

The invention relates to the technical field of biology, and particularly provides an endometrial organ culture method. By optimizing the endometrial organoid differentiation culture system, compared with an existing culture mode, the optimized culture system is easy to operate, the organoid with more complete physiological functions can be prepared without co-culture with stromal cells, continuous culture can be conducted for at least one year or above, and the obtained organoid is complete in secretion function and free of secondary pollution. The phenotype of cilia cells is more obvious.

The present invention relates to a method for preparing organ-specific mesenchymal cells from pluripotent stem cell-derived intestinal organoid stromal cells. By using cells derived from stromal cell layers adjacent to intestinal organoids for differentiation into organ-specific mesenchymal cells, the present invention can greatly increase the efficiency of differentiation into stromal cells through the regulation of retinoic acid (RA) and hedgehog (HH) signaling pathways, and can increase the expression of organ-specific markers without exhibiting undifferentiated state cell characteristics, and thus mesenchymal cells having well-simulated biological characteristics can be prepared.

In one embodiment, cells 12 are suspended inside a hollow capsule 11 including a semipermeable membrane, and the hollow capsule 11 is incubated in a culture medium to allow the cells 12 to aggregate inside the hollow capsule 11. The cells 12 are a mixture of dissociated target cells 14 and auxiliary cells 15 for assisting the aggregation of the target cells 14. The target cells 14 more easily aggregate in the presence of the auxiliary cells 15 than in the absence of the auxiliary cells 15. In another embodiment, dissociated cells 12 are suspended inside a hollow capsule 11 including a semipermeable membrane, and the hollow capsule 11 is incubated in a culture medium to allow the cells to aggregate inside the hollow capsule 11. The cells 12 include at least stromal cells. Thus, an aggregate 21 of the cells 12 is produced.

The invention provides a space-time 3D printing method for tumor microenvironment organoid, which comprises the following steps: printing shell gel microbeads, and printing core gel microbeads in the shell gel microbeads to obtain core-shell gel microbeads; carrying out irreversible cross-linking curing on the core-shell gel microbeads to form a stable structure, so as to obtain the tumor microenvironment organ-like model. In the process of printing the inner core gel microbeads in the shell gel microbeads, time dimension and / or space dimension regulation and control printing is carried out, so that the effect of constructing different tumor microenvironment characteristics is achieved. The'core-shell 'gel microbead structure is printed through space-time modulation, organoids and stromal cells can be positioned in the inner core gel layer and the outer shell gel layer respectively, organoid models of different tumor microenvironment characteristics of a space layered structure are constructed, self-assembly of tumor cells can be guided, the effect of regulating the initial state of the tumor cells is achieved, and the tumor microenvironment characteristic of the tumor cells is improved. The tumor organoid can keep a stable three-dimensional structure in the subsequent culture process.

The invention discloses a fructus lycii pigment composition for treating benign prostatic hyperplasia and application. The fructus lycii pigment composition comprises lycium barbarum red, zeaxanthine, xanthophyll and beta-carotene. The fructus lycii pigment composition provided by the invention can effectively inhibit prostate stromal cell proliferation, inhibit prostate tissue hyperplasia in vivo, improve the pathological morphology of prostate tissue, regulate the androgen level, inhibit inflammatory response and relieve oxidative damage. The traditional Chinese medicine is applied to clinical treatment of prostatic hyperplasia and has the advantages of remarkable curative effect and low toxic and side effects.

The invention discloses a stem cell-derived function-enhanced mesenchymal stromal cell as well as a preparation method and application thereof. The preparation method comprises the following steps: inserting an IL-10 gene coding sequence and a CD47 gene coding sequence into a human pluripotent stem cell; a neural crest cell differentiation culture medium containing a Wnt pathway agonist and an ALK5 inhibitor is used for carrying out induced differentiation culture on the CD47 positive human pluripotent stem cells to obtain the neural crest cells. The neural crest cells are subjected to induced differentiation culture by adopting a transition culture medium containing an epidermal growth factor, a fibroblast growth factor 2 and a cell apoptosis inhibitor and a mesenchymal stromal cell differentiation culture medium containing the epidermal growth factor, the fibroblast growth factor 2 and a platelet growth factor in sequence; according to the present invention, with the combination of the specific embodiments, the obtained mesenchymal stromal cell highly expresses CD47 and IL-10, the expression of the CD47 can help the transplanted cell escape from the attack of the immune system and prolong the cell survival time, and the expression of the IL-10 can be used for anti-inflammation.

Described herein are methods for treatment of kidney disease, comprising administering to a patient in need thereof a cell-derived product to the perirenal adipose tissue (PRAT) of the patient. Optionally, the cell derived product is a plurality of mesenchymal stromal cells. Other diseases may be treated using this method including: a disease of the liver, cardiovascular disease, inflammatory disease, fibrotic disease, autoimmune disease, and disease of a visceral organ.

The invention discloses a bionic bone marrow microenvironment assembly for hematopoietic stem cell in-vitro amplification and a preparation method. The bone marrow microenvironment assembly comprises a three-dimensional scaffold and osteoblasts (OBs), wherein the three-dimensional scaffold comprises chitosan (CS) and sodium alginate (Alg) which are prepared into mixed gel, and the mixed gel is freeze-dried to prepare the three-dimensional scaffold; wherein the osteoblasts (OBs) are obtained by culturing and induced differentiation of umbilical cord mesenchymal stem cells (MSCs) inoculated on a three-dimensional scaffold, and the osteoblasts (OBs) as stromal cells and the three-dimensional scaffold jointly form the hematopoietic stem cell in-vitro amplification bionic bone marrow microenvironment assembly; in the hematopoietic stem cell in-vitro amplification bionic bone marrow microenvironment assembly, the preparation of the three-dimensional scaffold comprises the processes of freezing, remelting, freezing, crosslinking, freeze-drying and the like, so that a three-dimensional space form with wrinkles on the pore surface and pore size distribution between 70 microns and 400 microns is generated in the three-dimensional scaffold, and the three-dimensional space form is closer to a real stem cell niche; therefore, the practical application effect of the bionic bone marrow microenvironment assembly for in-vitro amplification of the hematopoietic stem cells is further improved.

The present invention provides a method of producing a population of mesenchymal stromal cells (MSC) of CD73 + CD44 +, CD90 +. The CD73 + CD44 +, CD90 + MSC is used in a method for producing terminally differentiated osteoblasts, adipoblasts and chondroblasts from pluripotent stem cells (PSCs). The differentiation methods include the use of a single agent-a WNT signaling pathway activator used on an adherent culture of PSC, such as a GSK3 [beta] inhibitor.

The present invention relates to CD73 + CD44 + , CD90 + A method for generating a population of mesenchymal stromal cells (MSCs) is provided. + CD44 + , CD90 + MSCs are used in methods to generate terminally differentiated osteogenic, adipogenic, and chondrogenic cells from pluripotent stem cells (PSCs), which involve the use of a single agent, a WNT signaling pathway activator (e.g., a GSK3β inhibitor), in adherent cultures of PSCs.

The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.

It forms an object of the present invention a hollowed scaffold and a method to obtain the same, said hollowed scaffold being a milli-scale vessel-like structure comprising a microenvironment, a lumen, and a vessel wall, said microenvironment and said vessel wall being made, independently the one from the other, of a matrix, wherein in said matrix constituting said microenvironment stromal cells are embedded, and wherein in said matrix constituting said vessel walls endothelial cells are embedded. Additional objects of the present invention are a bioreactor comprising the hollowed scaffold and method to study cells in tissue-like vascularised constructs.

The invention discloses a preparation method of composite microspheres for regulating and controlling a local inflammation microenvironment and promoting nerve regeneration. The method comprises the following steps: preparing liposome loaded with ginsenoside Rg1; preparing a GM microsphere loaded with a stromal cell-derived factor 1 alpha (SDF1 alpha); and preparing the inflammation regulation nerve regeneration promoting composite microspheres. The composite microsphere can reduce inflammatory response, reduce scar tissue formation, promote angiogenesis, continuously release SDF1 alpha and promote endogenous stem cell recruitment and neural differentiation. Therefore, the composite microsphere is a functional biological scaffold for firstly regulating and controlling local microenvironment inflammation of spinal cord injury and then promoting collection and differentiation of endogenous stem cells for innovative sequential inflammation regulation and nerve regeneration, and a new strategy is provided for treating spinal cord injury by tissue engineering.

The invention provides a preparation method of a mesenchymal stem cell exosome incubated by a GLP-1 medicine. The preparation method comprises the following steps: S1, preparing materials; s2, separating the human adipose tissue-derived stromal cells; s3, cell surface marker protein detection; s4, carrying out GLP-1 incubation; and S5, extracting the exosome. According to the preparation method of the mesenchymal stem cell exosome incubated with the GLP-1 medicine, the human adipose tissue-derived stromal cell exosome is collected in a specific mode, the whole process is simple and convenient, the obtained human adipose tissue-derived stromal cell exosome is stable in effect, damage of myocardial cells after myocardial infarction can be effectively relieved, the heart function can be enhanced, and the human adipose tissue-derived stromal cell exosome can be used for treating myocardial infarction. The compensatory cardiac machine load is reduced, and the heart failure is relieved.

It was discovered that by binding to CTCF which is important for maintaining chromosomal structures, hSATII RNA inhibits the function thereof, changes chromosome interaction, and induces transcription of inflammation-associated genes. It has also been discovered that cell death can be selectively induced in senescent cells and cancer cells by suppressing hSATII RNA expression. From the obtained results, it has been found that cancer treatment which targets senescent stromal cells and cancer cells can be performed with a substance that suppresses hSATII RNA or a substance that increases CTCF expression. In addition, cancer can be detected early by measuring the expression and activity of hSATII RNA and CTCF, and an epigenomic change of the hSATII DNA region. Thus, it is possible to provide a therapeutic drug for a cancer associated with cellular senescence, a method for screening thereof, and a test support method.

Methods of differentiating a mesenchymal stromal cell (MSC) to a first non-MSC cell fate, the method comprising contacting the MSC with extracellular vesicles (EVs), matrix-bound vesicles (MBVs) or a combination thereof are provided. Methods of producing artificial tissue by culturing MSCs with two sets of vesicles each comprising EVs, MBVs or both that differentiate MSCs to two different non-MSC cell fates, methods of culturing with reduced growth factors and method of differentiating an MSC to a muscle cell fate are also provided.

Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some cases, the antibodies are cross-reactive with one or more non-human animal uPAR polypeptides, such as non-human primate uPAR, e.g., cynomolgus monkey uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins, and conjugates of the present disclosure to treat conditions associated with uPAR expression and / or activity are also provided. In some embodiments, the condition associated with uPAR expression and / or activity is cancer. Non-limiting examples of such cancers include cancers characterized by cancer cells expressing uPAR on their surface, cancers characterized by stromal cells within the tumor microenvironment expressing uPAR on their surface, and the like.

The current invention relates to a composition comprising extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs). The EVs are part of a population of particles in the composition having a particle size of between 0.05 and 0.22 micron. The concentration of these particles is at least 1×1011 particles per ml of composition. At least 90% of the particles with particle size of between 0.05 and 0.22 micron are EVs. The EVs are defined by having a concentration of intra-vesicular Annexin V of at least 40 ng / ml and a concentration of extra-vesicular Annexin V of less than 1 ng / ml. Uses of the composition also are disclosed.

The utility model relates to a kind of human adenomyosis ectopic epithelium and stromal cell separation culture devices. The device includes L-shaped base, fixed tube, centrifugal tube, filter separation component. Two centrifugal tubes are used to collect stromal cell and epithelial cell respectively, and the top end of centrifugal tube is connected with top cover. Filter separation component includes mounting ring, locating ring, flexible filter screen, annular frame and positioning mechanism. Mounting ring is horizontally arranged, locating ring is peripherally arranged on mounting ring, and locating ring is adapted to the top end of centrifugal tube, filter screen is arranged at the bottom of mounting ring, the bottom of annular frame is connected with the bottom surface of flexible filter screen, gap is provided between the top of annular frame and mounting ring, and annular frame is limited by positioning mechanism. Compared with prior art, the utility model can simplify the separation process of human adenomyosis ectopic epithelium and stromal cell, reduce cleaning work, and is suitable for laboratory culture operation.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

The invention discloses application of EPO (erythropoietin) in preparation of a medicine for preventing and treating corneal injury, belongs to the technical field of medicines, and focuses on innovative application of EPO in preparation of the medicine for preventing and treating corneal injury. The cornea is used as a key structure of eyes and is easily damaged by various factors such as mechanical trauma, chemical injury, infection and diabetes, and more than ten millions of people in the world are troubled by cornea blindness. The invention finds that EPO has a remarkable treatment effect on corneal injury, and can promote proliferation and migration of corneal epithelium and stromal cells, increase the generation of extracellular matrix and enhance the tolerance of corneal epithelium cells and corneal stromal cells to high-level sugar. The medicine can be a self-freeze-drying preparation or a solution preparation, the administration modes are diversified, and various eye local injection, eye drop, gene therapy and the like are covered. Refined treatment schemes are provided for corneal injuries of different pathogenesis, a new way is developed for treatment of the corneal injuries, the corneal blindness rate is expected to be reduced, and the development of ophthalmic medicine is promoted.